On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...